News | Heart Valve Technology | July 21, 2015

GlobalData Analyst: Edwards Lifesciences, Medtronic Devices to Redefine TAVR Space

Report notes Sapien 3, CoreValve Evolut R have corrected critical flaws of early models, demonstrate growing acceptance of TAVR

GlobalData, TAVR, Edwards, Medtronic, CoreValve Evolut R, Sapien 3

Sapien 3 image courtesy of Edwards Lifesciences
 

July 21, 2015 — The recent U.S. Food and Drug Administration (FDA) approvals of two next-generation transcatheter aortic valve replacements (TAVR) devices will transform the U.S. market for TAVR procedures over the next decade, according to an analyst with research and consulting firm GlobalData.

According to Premdharan Meyyan, GlobalData's analyst covering medical devices, Edwards Lifesciences' Sapien 3 and Medtronic's CoreValve Evolut R have corrected some of the critical flaws inherent in earlier models, namely the Sapien XT and CoreValve. As a result, these devices have reduced mortality and complication rates in patients with severe aortic stenosis.

Meyyan said:"The FDA's Sapien 3 approval is expected to solidify Edwards Lifesciences' TAVR market lead. The company has improved upon Sapien XT's design by incorporating a polyethylene terephthalate skirt into its product, which minimizes the incidence of paravalvular regurgitation following valve implantation. GlobalData expects this feature to become an industry standard moving forward.

"Additionally, clinical data evaluating safety and efficacy of the Sapien 3 has proved strong so far, with 30-day outcomes from the PARTNER II trial demonstrating a 2.2 percent all-cause mortality rate in inoperable/high-risk patients, compared to the 3.5 percent rate in patients with the Sapien XT."

The analyst added that Medtronic's CoreValve Evolut R updates the original CoreValve design to include a thinner delivery system using a 14F sheath, compared to the original device's 18F sheath. This enables the product to be used in a wider range of artery sizes, expanding the treatment to a greater number of patients.

Unlike the Sapien 3, CoreValve Evolut R is fully repositionable and retrievable, allowing physicians greater control during the fitting procedure. Key opinion leaders have noted the product's easy-to use and intuitive repositionability function, which GlobalData also expects to see in future transcatheter valves.

Meyyan continued: "The approvals of the Sapien 3 and CoreValve Evolut R highlight the increasing adoption and acceptance of TAVR within the medical community as a standard treatment option for valvular heart disease patients.

"Furthermore, they will give Edwards Lifesciences and Medtronic an edge over other TAVR players, such as Boston Scientific and Symetis, which have also been attempting to seize shares in a growing market expected to be worth $3.02 billion by 2020," the analyst concluded.

For more information: www.globaldata.com

Related Content

SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart | January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Videos | Structural Heart | November 09, 2016
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart | August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
Videos | Structural Heart | June 30, 2016
Interview with Stephen Little, M.D., medical director of the Valve Clinic at the Houston Methodist DeBakey Heart and
AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation
News | Structural Heart | May 16, 2016
At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a...
CABG, mitral valve repair, ischemic mitral regurgitation, IMR, study, ACC 2016
News | Structural Heart | April 11, 2016
Just-released two-year follow-up data comparing coronary-artery bypass grafting (CABG) with combined CABG and mitral-...
V-Wave Interarterial Shunt, first human results, The Lancet, heart failure, HF
News | Structural Heart | March 28, 2016
V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF),...
News | Structural Heart | March 02, 2016
Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards...
AtriCure, AtriClip, ATLAS study, first patient enrolled, POAF, post-operative atrial fibrillation
News | Structural Heart | February 18, 2016
AtriCure Inc. announced that the first patient was enrolled and treated at PinnacleHealth Hospitals in Harrisburg, Pa...
HeartWare, terminated acquisition, Valtech Cardio
News | Structural Heart | February 10, 2016
February 10, 2016 — HeartWare International Inc. and Valtech Cardio Ltd.
Overlay Init